MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Relmada Therapeutics P/E Ratio 2011-2026 | RLMD
Annual P/E Ratio Relmada Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.3 | -2.36 | -1.64 | -0.455 | -2.86 | -8.57 | -3.11 | -1.75 | -1.56 | -7.49 | -3.46 | -1.75 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.455 | -8.57 | -3.27 |
P/E Ratio of other stocks in the Drug manufacturers industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
-0.0278 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-0.024 | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-60.1 | $ 5.72 | -2.39 % | $ 85 M | USA |
 |
HEXO Corp.
HEXO
|
-0.257 | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.97 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-1.71 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-1.15 | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.679 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-4.35 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-0.0895 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-5.04 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-254 | $ 2.79 | 0.72 % | $ 1.07 B | Canada |
 |
Athenex
ATNX
|
-0.111 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
-376 | $ 33.46 | 1.09 % | $ 1.23 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-14.7 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-10.4 | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
9.11 | $ 2.48 | 4.2 % | $ 314 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
9.54 | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
-0.237 | $ 1.02 | - | $ 110 M | Canada |
 |
Pacira BioSciences
PCRX
|
-11.8 | $ 23.21 | 1.53 % | $ 1.07 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-1.06 | $ 1.11 | 1.83 % | $ 1.38 M | USA |
 |
Solid Biosciences
SLDB
|
-3.57 | $ 6.57 | 2.5 % | $ 575 M | USA |
 |
Aurora Cannabis
ACB
|
141 | $ 3.38 | -0.88 % | $ 185 M | Canada |
 |
Jupiter Wellness
JUPW
|
-0.0479 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-0.108 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-3.31 | $ 1.08 | 0.93 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
-0.821 | $ 5.17 | 2.78 % | $ 3.19 B | Canada |
 |
Evolus
EOLS
|
-5.26 | $ 6.7 | 0.3 % | $ 432 M | USA |
 |
Sundial Growers
SNDL
|
-0.00386 | $ 1.46 | 0.69 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
8.59 | $ 7.95 | -0.63 % | $ 425 M | USA |
 |
Veru
VERU
|
-3.74 | $ 3.1 | 3.33 % | $ 45.4 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-0.0473 | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-1.75 | $ 0.72 | -0.69 % | $ 2.9 M | USA |
 |
Assertio Holdings
ASRT
|
-2.48 | $ 23.46 | 0.13 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
7.07 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-5.6 | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
12.9 | $ 5.17 | 1.17 % | $ 1.92 B | Canada |
 |
PetIQ
PETQ
|
186 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
-10 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-0.36 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-4.41 | $ 4.36 | -2.02 % | $ 218 M | USA |
 |
PLx Pharma
PLXP
|
-2.59 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
336 | $ 16.2 | 1.69 % | $ 18.9 B | USA |
 |
Zomedica Corp.
ZOM
|
-3.97 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.536 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-6.36 | $ 0.69 | 3.81 % | $ 24.8 M | USA |
 |
Tricida
TCDA
|
-2.31 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.862 | $ 0.72 | 0.75 % | $ 3.09 M |  China |
 |
TherapeuticsMD
TXMD
|
-40.5 | $ 1.88 | - | $ 21.7 M | USA |